People: Zealand Pharma A/S (ZEAL.OQ)

ZEAL.OQ on NASDAQ Stock Exchange Global Select Market

17 Jul 2018
Change (% chg)

$0.03 (+0.19%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Crane, Rosemary 

Ms. Rosemary A. Crane has been Independent Vice Chairman of the Board at Zealand Pharma A/S since April 21, 2015. Ms. Rosemary Crane has been CEO of Mela Sciences (2013-2014) and Epocrates (2008-2011), besides having held a number of leading positions in Johnson & Johnson and BMS. She is Member of the Board of Teva Pharmaceuticals Industries Ltd. and Unilife. Rose has a BA in Communication from the State University of New York, MBA from Kent State University.

Basic Compensation

Total Annual Compensation, DKK 400,000
Restricted Stock Award, DKK --
Long-Term Incentive Plans, DKK --
All Other, DKK --
Fiscal Year Total, DKK 400,000

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --